Clinical Watch: August 2018

August 29, 2018

In this issue of Clinical Watch, we discuss the first cannabis-derived drug approved by the FDA. We suggest criteria for a long-acting atypical antipsychotic used to initiate therapy with aripiprazole and summarize a review article of new and investigational migraine treatments. Lastly, we discuss the updated treatment guidelines for Crohn’s disease.

For more information about our solutions, please visit conduent.com/pharmacysolutions.

Previous Flipbook
Clinical Watch: September 2018
Clinical Watch: September 2018

Next Flipbook
Clinical Watch: July 2018
Clinical Watch: July 2018